Skip to main content
About
Executive Team
Board of Directors
How We Operate
Quality
Capabilities
Locations
News
Products
Contract Manufacturing
Investors
Careers
Careers
Benefits
Available Positions
Application
Contact
Contact Us
Locations
News
Overview
News
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Investment Calculator
Analyst Coverage
Financials
Quarterly Results
Annual Reports
SEC Filings
Governance
Governance Documents
Executive Management
Board of Directors
Committee Composition
Resources
Investor FAQs
Information Request Form
Investor Email Alerts
Investor Contacts
Site Search
Normal
Press release year list
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2009
2008
05/20/2022
ANI Pharmaceuticals to Present at Upcoming Healthcare Investor Conferences
05/10/2022
ANI Pharmaceuticals Reports First Quarter 2022 Results; Provides Purified Cortrophin® Gel Net Revenue Guidance and Full-Year 2022 Total Company Net Revenue Guidance of $295 Million to $315 Million
04/19/2022
ANI Pharmaceuticals to Discuss First Quarter 2022 Financial Results on May 10, 2022
04/11/2022
ANI Pharmaceuticals Announces the Launch of Misoprostol Tablets
03/22/2022
ANI Pharmaceuticals Appoints Experienced Commercial Leader, Renee P. Tannenbaum, Pharm.D., MBA, to Board of Directors
03/15/2022
ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; Strong Foundation in Place to Drive Sustainable Growth
03/07/2022
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022
02/24/2022
ANI Pharmaceuticals Strengthens Rare Disease Business Unit Leadership Team
01/24/2022
ANI Pharmaceuticals Announces Commercial Availability of Purified Cortrophin™ Gel (Repository Corticotropin Injection USP) for Multiple Chronic Autoimmune Disorders
01/03/2022
ANI Pharmaceuticals to Present at the H.C. Wainwright Bioconnect Virtual Conference